Maintenance. We are currently updating the site. Please check back shortly
Members login
  • TrustLaw
  • Members Portal
Subscribe Donate

Merck's grass pollen allergy drug wins U.S. approval

Source: Reuters - Mon, 14 Apr 2014 23:57 GMT
Author: Reuters
hum-dis hum-peo
Tweet Recommend Google + LinkedIn Email Print
Leave us a comment

April 14 (Reuters) - Merck & Co said the U.S. Food and Drug Administration on Monday approved its grass pollen allergy drug Grastek, becoming the second such immunotherapy treatment to be given the go-ahead in recent weeks.

The company, which developed the tablet with Denmark's ALK Abello, said it expects to launch the drug, approved for patients age 5 to 65, in the United States by late April.

Immunotherapies work by boosting the body's immune system and making it less sensitive to allergens.

Grastek contains extracts of the timothy grass allergen. The tablet is placed under the tongue and dissolves.

An advisory committee to the FDA unanimously recommended approval of the drug in December. Panelists also called for post-approval studies to test the product's safety in children, citing side effects such as lip swelling, throat irritation and oral blistering.

Earlier this month, the FDA approved Stallergenes' immunotherapy treatment for five types of grass pollen.

The French company has said it sees a potential U.S. market of nearly 3 million patients that will eventually be worth $1 billion in annual sales for these types of drugs.

Merck's pollen treatment received regulatory approval in Canada in February and has been available in Europe since 2006 under the name Grazax.

Merck shares closed at $55.57 Monday on the New York Stock Exchange.

(Reporting by Natalie Grover in Bangalore and Susan Kelly in Chicago; Editing by Savio D'Souza, Bernard Orr)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.

comments powered by Disqus
Most Popular
TOPICAL CONTENT
Topical content
LATEST SLIDESHOW

Latest slideshow

See allSee all
FEATURED JOBS
Featured jobs